Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP) potentiate the glutamate-evoked release of arachidonic acid from mouse cortical neurons. Evidence for a cAMP-independent mechanism.

Détails

ID Serval
serval:BIB_5192
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP) potentiate the glutamate-evoked release of arachidonic acid from mouse cortical neurons. Evidence for a cAMP-independent mechanism.
Périodique
Journal of biological chemistry
Auteur⸱e⸱s
Stella N., Magistretti P.J.
ISSN
0021-9258
Statut éditorial
Publié
Date de publication
1996
Peer-reviewed
Oui
Volume
271
Numéro
39
Pages
23705-23710
Langue
anglais
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't - Publication Status: ppublish
Résumé
Glutamatergic neurotransmission is associated with release of arachidonic acid (AA) from membrane phospholipids of both neurons and astrocytes. Since free AA has been shown to enhance glutamate-mediated synaptic transmission, it can be postulated that glutamate release and AA formation constitute a positive feed-back mechanism for sustained excitatory neurotransmission. In the present study, we examined whether the glutamate-evoked release of AA could be modulated by peptides. Using mouse cortical neurons in primary cultures, we show that the release of AA evoked by glutamate is potentiated by vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide (PACAP). This effect is mediated through the activation of PACAP I receptors. However, several arguments show that this potentiating mechanism does not involve the cAMP/PKA pathway. 1) Increasing intracellular cAMP by either cholera toxin, forskolin, or 8-Br-cAMP treatments does not affect the glutamate-evoked release of AA; 2) potentiation of the glutamate response by PACAP is not prevented by the PKA inhibitor 8-Br-Rp-cAMPS. Also, an involvement of the phospholipase C protein kinase C pathways is unlikely since inhibitors of both phospholipase C (i.e. U-73122) and protein kinase C (i.e. Ro 31-8220) do not affect the potentiation of the glutamate response by PACAP. These observations indicate an effect mediated by PACAP I receptors, which does not involve the second messenger pathways classically associated with activation of this type of receptors. Furthermore, results indicate that this potentiating mechanism mediated by PACAP I receptor acts at a level downstream of the glutamate receptor-mediated calcium influx.
Mots-clé
Animals, Arachidonic Acid, Calcium, Cells, Cultured, Cerebral Cortex, Cyclic AMP, Cyclic AMP-Dependent Protein Kinases, GTP-Binding Protein alpha Subunits, Gs, Glutamates, Mice, Neuropeptides, Neurotransmitter Agents, Pituitary Adenylate Cyclase-Activating Polypeptide, Receptors, AMPA, Receptors, N-Methyl-D-Aspartate, Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide, Receptors, Pituitary Hormone, Signal Transduction, Type C Phospholipases, Vasoactive Intestinal Peptide
Pubmed
Web of science
Création de la notice
19/11/2007 12:41
Dernière modification de la notice
20/08/2019 14:07
Données d'usage